Molecular tumor board
- Authors: La Mantia M.; Busuito G.; Spinnato V.; Gristina V.; Galvano A.; Cutaia S.; Barraco N.; Perez A.; Cusenza S.; Incorvaia L.; Badalamenti G.; Russo A.; Bazan V.
- Publication year: 2022
- Type: Capitolo o Saggio
- OA Link: http://hdl.handle.net/10447/625457
Abstract
The new multidisciplinary approach, called “Molecular Tumor board”, arises from a collaboration of specialists and subspecialists, from a variety of fields, who meet to review and discuss cancer cases (general or site-specific), in order to provide the best treatment planning and reach a possibly better outcome for each cancer patient. Tumor Boards represent the involvement of all relevant disciplines in the treatment evaluation and planning process, allowing physicians to improve their approach to specific cancers by reviewing their cases and reconsidering changes in diagnosis and management, sharing them with all board members, and helping to ensure judicious use of health care resources. In this chapter, we aimed to summarize all the recent evidence on the molecular tumor board.